NSE · NGLFINE · Pharmaceuticals
NGL Fine Chem Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹157 Cr with net profit ₹13 Cr — a 8.54% net margin, versus 12.03% the period before.
Shareholding
As of 2026-09-30
- Promoter72.49%
- Public27.46%
- FII0.04%
- DII0%
12,939 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.83× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #9 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹3,03,749 Cr | 88.88 | 16.95 | 18.69% | 27.59% |
| Acutaas Chemicals Limited | ₹33,069 Cr | 75.3 | 17.82 | 23.64% | 27.58% |
| Neuland Laboratories Ltd. | ₹27,043 Cr | 59.76 | 13.33 | 22.3% | 19.61% |
| Jubilant Pharmova Ltd. | ₹15,356 Cr | 39.58 | 2.17 | 5.62% | 4.11% |
| SMS Pharmaceuticals Ltd. | ₹4,758 Cr | 40.68 | 5.65 | 13.88% | 12.04% |
| Aarti Drugs Ltd. | ₹4,631 Cr | 20.1 | 2.75 | 13.61% | 8.03% |
| Hikal Limited | ₹2,743 Cr | 38.56 | 2.32 | 6.03% | -27.19% |
| Beta Drugs Limited | ₹2,021 Cr | 38.93 | 4.62 | 11.86% | 11.69% |
| NGL Fine Chem Limited(this company) | ₹1,879 Cr | 29.45 | 5.18 | 17.6% | 11.11% |
| Fermenta Biotech Ltd. | ₹1,395 Cr | 30.04 | 3.33 | 12.29% | 10.01% |
AI analysis
AI-generated · google/gemini-2.5-flashNGL Fine Chem Limited (NGLFINE) operates in the Pharmaceuticals sector. The company has a market capitalization of Rs 2000 Cr. Its 52-week high is Rs 3329 and its 52-week low is Rs 1175.5.
Positives
- +The company's debt-to-equity ratio is low at 0.2.
- +Promoter holding is high at 72.736% as of Mar 2026.
- +Quarterly net profit rose from Rs 0.54 Cr in March 2025 to Rs 13.49 Cr in March 2026.
Negatives
- −The profit margin is 9.59%.
- −The company recorded a negative net profit of -0.52 Cr for the annual period ending Mar 2025.
- −The company is under 'LT-ASM · ASM 1' surveillance.
- −Foreign Institutional Investors (FII) holding is low at 0.0273% as of Mar 2026.
Financial performance
NGL Fine Chem Limited reported quarterly revenue of Rs 149.23 Cr in Mar 2026, marking an increase from Rs 94.97 Cr in Mar 2025. Net profit also rose to Rs 13.49 Cr in Mar 2026 from Rs 0.54 Cr in Mar 2025. Annual revenue for Mar 2026 was Rs 144.75 Cr, compared to Rs 93.02 Cr in Mar 2025 where net profit was -0.52 Cr.
Profitability & Returns
The company’s profit margin stands at 9.59%. Return on equity (ROE) is 14.62% and Return on Capital Employed (ROCE) is 15.3699%. Earnings per share (EPS) for the most recent period is Rs 77.87. The P/E ratio is 148.3.
Balance Sheet
The book value per share is Rs 532.73. The debt-to-equity ratio is 0.2, indicating a relatively low level of debt compared to equity. The company’s dividend yield is 5%.
Ownership & Pledges
Promoter holding in NGL Fine Chem Limited is 72.736% as of Mar 2026. There were no shares pledged by the promoters as of Mar 2026.
Regulatory & Surveillance
NGL Fine Chem Limited is currently under surveillance with the label 'LT-ASM · ASM 1', indicating it is subject to long-term additional surveillance measures.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.